Objective: To assess the impact of postoperative complications on the receipt of adjuvant
chemotherapy. Background: Randomized trials have demonstrated that adjuvant …

Background Multiple trials have demonstrated a survival benefit for adjuvant chemotherapy
after resection of pancreatic adenocarcinoma. This study aimed to identify the rate for …

Background The impact of postoperative complications on the administration of adjuvant
therapy following pancreaticoduodenectomy (PD) for adenocarcinoma is still unclear …

Background Randomized trials have demonstrated a benefit associated with adjuvant
therapy for pancreatic cancer, and retrospective studies have demonstrated improvements …

BACKGROUND: Surgical resection remains the only potentially curative option for patients
with pancreatic adenocarcinoma (PAC). Advances in surgical technique and perioperative …

Adjuvant chemotherapy after pancreatoduodenectomy for pancreatic cancer is currently
considered standard of care. In this nationwide study, we investigated which characteristics …

Importance Surgery followed by adjuvant chemotherapy or chemoradiation is widely used to
treat resectable pancreatic cancer. Although studies suggest initiation of adjuvant therapy …

Background Neoadjuvant therapy (NAT) is used for borderline-resectable or locally
advanced pancreatic cancer (PDAC) and exhibits promising results in terms of pathological …

Introduction The impact of neoadjuvant therapy on postpancreatectomy complications is
inadequately described. Methods Data from the NSQIP Pancreatectomy Demonstration …

Importance Clinical outcomes after curative treatment of resectable pancreatic ductal
adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of …